Clinical data on selective inhibitors of JAK2 or JAK1 and JAK2 are promising and suggest that they improve certain MPN-related symptoms and constitutional signs, as well as reduce splenomegaly. Here, JAK2 is linked to myeloproliferative neoplasm.